Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration
暂无分享,去创建一个
[1] R. Levine. Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment , 1988 .
[2] Xiaoling Liu,et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. , 2014, Ophthalmology.
[3] P. Rosenfeld,et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.
[4] Ruikang K. Wang,et al. Original articleOptical Coherence Tomography Angiography of Asymptomatic Neovascularization in Intermediate Age-Related Macular Degeneration , 2016 .
[5] N. Bressler,et al. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. , 2015, Ophthalmology.
[6] E. Souied,et al. Optical Coherence Tomography Angiography Features of Type 3 Neovascularization in Age-Related Macular Degeneration. , 2016, Developments in ophthalmology.
[7] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[8] G Richard,et al. [Optical coherence tomography in geographic atrophy--a clinicopathologic correlation]. , 2001, Klinische Monatsblatter fur Augenheilkunde.
[9] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[10] P. Rosenfeld,et al. PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR ENDOTHELIAL GROWTH FACTOR TRAP-EYE) , 2011, Retina.
[11] Glenn J Jaffe,et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.
[12] P. Rosenfeld,et al. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[13] T. Cox,et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. , 2002, Archives of ophthalmology.
[14] S. Sadda,et al. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus. , 2014, Ophthalmology.
[15] Usha Chakravarthy,et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.
[16] Terje R Pedersen,et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. , 2015, Ophthalmology.
[17] Christian Simader,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[18] M. Pfau,et al. Das klinische Ergebnis eines Therapiewechsels von Ranibizumab und/oder Bevacizumab zu Aflibercept bei neovaskulärer altersabhängiger Makuladegeneration (AMD) , 2016, Klinische Monatsblätter für Augenheilkunde.
[19] S. Lightman,et al. A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept , 2016, Journal of ophthalmology.
[20] P. Rosenfeld,et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.
[21] P. Rosenfeld,et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. , 2006, Ophthalmology.
[22] Mark Michels,et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.
[23] J. P. Sy,et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. , 2006, Ophthalmology.
[24] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[25] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[26] G. Ying,et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.
[27] Hiroshi Ishikawa,et al. Optical coherence tomography: history, current status, and laboratory work. , 2011, Investigative ophthalmology & visual science.
[28] B. Lujan,et al. Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography. , 2011, Ophthalmology.
[29] A. Hassenstein,et al. Optische Kohärenztomographie bei geographischer Atrophie - eine klinisch-pathologische Korrelation1 , 2001 .
[30] D. Sarraf,et al. TEARS OF THE RETINAL PIGMENT EPITHELIUM: An Old Problem in a New Era , 2007, Retina.
[31] Joan W. Miller,et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. , 1996, Archives of ophthalmology.
[32] G. Rücker,et al. Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis , 2015, PloS one.
[33] S. Sadda,et al. Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment. , 2015, Ophthalmic surgery, lasers & imaging retina.
[34] D. Guyer,et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease , 2006, Nature Reviews Drug Discovery.
[35] Jesse J. Jung,et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. , 2014, American journal of ophthalmology.
[36] P. Rosenfeld,et al. Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. , 2014, Ophthalmic surgery, lasers & imaging retina.
[37] M. A. Mahr,et al. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States. , 2016, Ophthalmology.
[38] A. D. de Vos,et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.
[39] Napoleone Ferrara,et al. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. , 2005, Biochemical and biophysical research communications.
[40] P. Rosenfeld,et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2006, Ophthalmology.
[41] G. Emerson. OPTICAL COHERENCE TOMOGRAPHY FINDINGS DURING PEGAPTANIB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2007, Retina.
[42] R. Apte,et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration , 2015, British Journal of Ophthalmology.
[43] Eric M. Moult,et al. Optical Coherence Tomography Angiography of Dry Age-Related Macular Degeneration. , 2016, Developments in ophthalmology.
[44] William J Feuer,et al. Spectral domain optical coherence tomographic imaging of geographic atrophy. , 2008, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[45] R. Guymer,et al. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration , 2015, Expert review of clinical pharmacology.
[46] B. Nan,et al. Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade. , 2014, Investigative ophthalmology & visual science.
[47] P. Kaiser,et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. , 2011, Ophthalmology.
[48] Glenn J Jaffe,et al. Subretinal Hyperreflective Material in the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2015, Ophthalmology.
[49] William J Feuer,et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[50] S. Kishi,et al. CORRELATION OF OPTICAL COHERENCE TOMOGRAPHY WITH ANGIOGRAPHY IN RETINAL PIGMENT EPITHELIAL DETACHMENT ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION , 2004, Retina.
[51] M. Blumenkranz,et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. , 2005, Ophthalmology.
[52] G. Pron,et al. Optical Coherence Tomography Monitoring Strategies for A-VEGF-Treated Age-Related Macular Degeneration: An Evidence-Based Analysis. , 2014, Ontario health technology assessment series.
[53] Allen C Ho,et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.
[54] Jesse J. Jung,et al. TYPE 3 NEOVASCULARIZATION: Evolution, Association With Pigment Epithelial Detachment, and Treatment Response as Revealed by Spectral Domain Optical Coherence Tomography , 2015, Retina.
[55] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[56] K. Freund,et al. SUBRETINAL HYPERREFLECTIVE EXUDATION ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.
[57] Glenn J Jaffe,et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.
[58] William J Feuer,et al. Comparison of geographic atrophy measurements from the OCT fundus image and the sub-RPE slab image. , 2013, Ophthalmic surgery, lasers & imaging retina.
[59] J. Winder,et al. Identification of lesion components that influence visual function in age related macular degeneration , 2003, The British journal of ophthalmology.
[60] B. Dolan. Optical Coherence Tomography of Ocular Diseases, 2nd ed , 2005 .
[61] D. Sarraf,et al. Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration. , 2016, Developments in ophthalmology.
[62] E S Gragoudas,et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.
[63] Usha Chakravarthy,et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial , 2013, The Lancet.
[64] Allen C Ho,et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2014, Ophthalmology.
[65] Philip J Rosenfeld,et al. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. , 2005, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[66] P. Campochiaro,et al. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. , 2015, American journal of ophthalmology.
[67] A. Ho,et al. Treatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimen. , 2015, American journal of ophthalmology.
[68] R. Guymer,et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration , 2016, British Journal of Ophthalmology.
[69] William J Feuer,et al. Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration. , 2016, Ophthalmology.
[70] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[71] Charles C Wykoff,et al. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. , 2015, Ophthalmology.
[72] J. Izatt,et al. Spectral domain optical coherence tomography imaging of geographic atrophy margins. , 2009, Ophthalmology.
[73] Lucas Wexler,et al. Optical Coherence Tomography Of Ocular Diseases , 2016 .
[74] L. Sandvik,et al. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: Two-Year Results. , 2016, Ophthalmology.
[75] E. Souied,et al. Optical Coherence Tomography Angiography of Type 2 Neovascularization in Age-Related Macular Degeneration. , 2016, Developments in ophthalmology.
[76] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.